Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes

Vaccine. 2002 Jan 15;20(7-8):1039-45. doi: 10.1016/s0264-410x(01)00450-9.


Recombinant replication-defective adenovirus expressing the CS gene from Plasmodium berghei (Ad-PbCS) was found to induce a strong CD8(+) T cell response after intra-dermal or -muscular immunisation. Boosting of an adenovirus-primed immune response with the replication-impaired poxvirus, modified vaccinia virus Ankara (MVA) led to enhanced immunogenicity and substantial protective efficacy. The recombinant adenoviral vaccine was capable of boosting to protective levels a CD8(+) T cell response primed by either a plasmid DNA vaccine, a recombinant Ty virus-like particle vaccine or recombinant MVA each expressing the same epitope or antigen. Complete protective efficacy after intradermal immunisation was observed with the adenovirus prime-MVA boost regime. This study identifies recombinant replication-defective adenovirus as an alternative to recombinant replication-defective poxviruses as boosting agents for the induction of strong protective CD8(+) T cell responses.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenoviridae / genetics
  • Animals
  • CD8-Positive T-Lymphocytes / immunology*
  • Female
  • Immunization, Secondary
  • Malaria / prevention & control*
  • Malaria Vaccines / immunology*
  • Mice
  • Mice, Inbred BALB C
  • Vaccines, DNA / immunology
  • Vaccines, Synthetic / immunology*
  • Vaccinia virus / genetics


  • Malaria Vaccines
  • Vaccines, DNA
  • Vaccines, Synthetic